Cordycepin, derived from fungi, shows promise in cancer therapy by inhibiting growth factor signaling pathways critical for ...

mTOR and tyrosine kinase inhibitors may play an increasing role in the management of well-differentiated neuroendocrine tumors in the future. Peptide receptor radiotherapy is a new treatment ...

The PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial is 100% enrolled; expect to report topline data for this cohort in late Q1 2025 or Q2 2025Approximately $264 million in cash, cash ...

Celcuity (CELC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Oliver McCammon ...

Nov. 12, 2024 — Glioblastoma is the most common kind of malignant brain tumor in adults. So far, no treatment has been able to make this aggressive tumor permanently disappear. The tumor cells ...

Q3 2024 Earnings Call Transcript November 14, 2024 Operator: Good afternoon, ladies and gentlemen, and welcome to the ...

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq ...

The global neuroendocrine carcinoma treatment market is poised for substantial growth, with revenue expected to reach USD ...

Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) GIST models – – Proof-of-concept study of ziftomenib plus ...

Unresectable (sometimes referred to as inoperable) cancer cannot be completely removed with surgery. This can be due to a variety of reasons, including tumor size, stage, and location. Although an ...

Nov. 11, 2024 — A team of scientists has used a novel approach to identify protein degraders that target Pin1, a protein involved in pancreatic cancer ... DNA Packaging Directly Affects How Fast ...